Innova Captab Limited
NSE: INNOVACAP · Pharmaceuticals
Snapshot
Unlock Innova Captab Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Innova Captab Limited is an integrated pharmaceutical company specialising in the research, development, and manufacturing of a wide range of generic formulations. The company operates as a contract development and manufacturing organisation (CDMO) while also marketing its own branded generic products through extensive distribution networks and e-commerce platforms.
Business Model
The company generates revenue through two primary streams: providing CDMO services to other pharmaceutical firms and selling branded generic products directly to the market. Its product portfolio spans numerous therapeutic categories, including cardiovascular, anti-diabetic, and respiratory medications, delivered in various formats such as tablets, capsules, and injectables.
Growth Outlook
Growth is expected to be driven by the expansion of its CDMO service offerings and the strengthening of its branded generic distribution network. The company continues to leverage its diverse manufacturing capabilities to address evolving healthcare needs in both domestic and international markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and manufacturing standards set by health authorities, where any failure to comply could lead to product recalls or facility shutdowns.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and margins for generic formulations.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients (APIs) and raw materials poses a risk to production continuity and cost stability.
- Pricing Controls. Government-mandated price caps on essential medicines in India may adversely impact the profitability of the company's generic product portfolio.
Start your research today
Unlock AI insights, financials, peers and live data on Innova Captab Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,749 Cr
TTM · consolidated
NET PROFIT
₹154 Cr
TTM · consolidated
EPS
₹26.91
TTM · consolidated
RETURN ON EQUITY
15.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · consolidated
P/E
43.7x
Q1 FY27 · consolidated
EV/EBITDA
26.3x
Q1 FY27 · consolidated
EBITDA MARGIN
15.4%
TTM · consolidated
NET PROFIT MARGIN
9.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Innova Captab LimitedINNOVACAP | ₹6,726 Cr | 43.68 | 26.28 | 34.5% | 15.4% | 15.0% | 17.4% | +27.9% |
Bliss GVS PharmaBLISSGVS | ₹7,098 Cr | 54.87 | 29.75 | 14.5% | 25.6% | 12.0% | 16.9% | +329.5% |
Supriya Lifescience LimitedSUPRIYA | ₹6,864 Cr | 34.60 | 22.66 | 28.1% | 34.5% | 18.1% | 23.8% | +30.1% |
Senores Pharmaceuticals Ltd.SENORES | ₹6,578 Cr | 50.30 | 29.26 | — | 34.7% | 15.2% | 18.4% | +102.9% |
Sun Pharma Advanced Research Company LimitedSPARC | ₹6,473 Cr | 4.09 | 4.28 | 2855.8% | 86.0% | 282.4% | 235.1% | +38.2% |
Jeena Sikho Lifecare LimitedJSLL | ₹6,418 Cr | 27.15 | 16.65 | — | 45.2% | 50.6% | 58.2% | -33.7% |
As of Q1 FY27
Financials
Innova Captab Limited
NSE: INNOVACAP · Pharmaceuticals
Snapshot
Unlock Innova Captab Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Innova Captab Limited is an integrated pharmaceutical company specialising in the research, development, and manufacturing of a wide range of generic formulations. The company operates as a contract development and manufacturing organisation (CDMO) while also marketing its own branded generic products through extensive distribution networks and e-commerce platforms.
Business Model
The company generates revenue through two primary streams: providing CDMO services to other pharmaceutical firms and selling branded generic products directly to the market. Its product portfolio spans numerous therapeutic categories, including cardiovascular, anti-diabetic, and respiratory medications, delivered in various formats such as tablets, capsules, and injectables.
Growth Outlook
Growth is expected to be driven by the expansion of its CDMO service offerings and the strengthening of its branded generic distribution network. The company continues to leverage its diverse manufacturing capabilities to address evolving healthcare needs in both domestic and international markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and manufacturing standards set by health authorities, where any failure to comply could lead to product recalls or facility shutdowns.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players exerting pressure on pricing and margins for generic formulations.
- Supply Chain Dependency. Reliance on external suppliers for active pharmaceutical ingredients (APIs) and raw materials poses a risk to production continuity and cost stability.
- Pricing Controls. Government-mandated price caps on essential medicines in India may adversely impact the profitability of the company's generic product portfolio.
Start your research today
Unlock AI insights, financials, peers and live data on Innova Captab Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,749 Cr
TTM · consolidated
NET PROFIT
₹154 Cr
TTM · consolidated
EPS
₹26.91
TTM · consolidated
RETURN ON EQUITY
15.0%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
17.4%
TTM · consolidated
P/E
43.7x
Q1 FY27 · consolidated
EV/EBITDA
26.3x
Q1 FY27 · consolidated
EBITDA MARGIN
15.4%
TTM · consolidated
NET PROFIT MARGIN
9.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27